Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hein Putter

Showing results (431-440 of 512) with videos related to

Pageof 52
Sort By:
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
Journal of the National Cancer Institute|September 20, 2017
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)Erik J Blok, Judith R Kroep, Elma Meershoek-Klein Kranenbarg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
British Journal of Cancer|October 27, 2021
Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4Sarah Ouahoud, Rutger J Jacobs, Ludmilla L Kodach, et al.
Annals of Epidemiology|September 26, 2016
Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA RegistryJacob J E Koopman, Anneke Kramer, Diana van Heemst, et al.
Frontiers in Immunology|June 30, 2025
Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusionEva A S Koster, Edouard F Bonneville, Peter A von dem Borne, et al.
Frontiers in Immunology|August 18, 2023
Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusionEva A S Koster, Edouard F Bonneville, Peter A von dem Borne, et al.
Breast Cancer Research and Treatment|November 23, 2013
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialVincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, et al.
The Lancet. Oncology|July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trialMarloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
Breast Cancer Research and Treatment|April 6, 2012
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort studyAnneke Q van Hoesel, Cornelis J H van de Velde, Peter J K Kuppen, et al.
Pageof 52

Showing results (431-440 of 512) with videos related to

Sort By:
Pageof 52
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
Journal of the National Cancer Institute|September 20, 2017
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)Erik J Blok, Judith R Kroep, Elma Meershoek-Klein Kranenbarg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
British Journal of Cancer|October 27, 2021
Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4Sarah Ouahoud, Rutger J Jacobs, Ludmilla L Kodach, et al.
Annals of Epidemiology|September 26, 2016
Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA RegistryJacob J E Koopman, Anneke Kramer, Diana van Heemst, et al.
Frontiers in Immunology|June 30, 2025
Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusionEva A S Koster, Edouard F Bonneville, Peter A von dem Borne, et al.
Frontiers in Immunology|August 18, 2023
Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusionEva A S Koster, Edouard F Bonneville, Peter A von dem Borne, et al.
Breast Cancer Research and Treatment|November 23, 2013
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialVincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, et al.
The Lancet. Oncology|July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trialMarloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
Breast Cancer Research and Treatment|April 6, 2012
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort studyAnneke Q van Hoesel, Cornelis J H van de Velde, Peter J K Kuppen, et al.
Pageof 52